STOCK TITAN

Baird-Sponsored Microwave Ablation Training Advances Thyroid Treatment

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Baird Medical (NASDAQ: BDMD) recently sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid nodule treatment. The program was led by Dr. Emad Kandil from Tulane University School of Medicine, with participation from Dr. Sean P. Nikravan and Dr. Erin H. Lin.

Participants observed seven live MWA procedures, gaining hands-on experience in precision targeting and workflow optimization. The training emphasized the technology's efficiency and potential for improved patient outcomes, including faster recovery times. Following the session, the physicians engaged in clinical discussions and received Certificates of Completion.

Chairwoman Haimei Wu emphasized the importance of hands-on training and expert collaboration in advancing MWA technology adoption for thyroid treatments.

Loading...
Loading translation...

Positive

  • Successfully conducted training program demonstrating MWA technology to potential adopters
  • Engagement of prominent medical professionals from major institutions
  • Practical demonstration of technology through 7 live procedures

Negative

  • None.

News Market Reaction 1 Alert

+25.40% News Effect

On the day this news was published, BDMD gained 25.40%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- Baird Medical (NASDAQ: BDMD), a leader in minimally invasive Microwave Ablation (MWA) technology, recently sponsored another advanced MWA training session in New Orleans. This program offered physicians practical experience with a state-of-the-art treatment designed to deliver quicker recovery and effective management of thyroid nodules.

Led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, the session welcomed participation from Dr. Sean P. Nikravan, MD, FACE, an endocrinologist based in Newport Beach, CA, and Dr. Erin H. Lin, DO, a specialist in Surgical Oncology and General Surgery from the University of California, Irvine. Both physicians had the opportunity to observe seven live MWA procedures, refine advanced techniques, and evaluate the unique capabilities of this groundbreaking technology. During the hands-on experience, they honed precision targeting of nodules and observed the high efficiency and quick execution of the procedure, emphasizing its streamlined workflow and potential to enhance patient outcomes.

Following the session, Dr. Nikravan and Dr. Lin participated in post-training discussions with Dr. Kandil, exchanging valuable clinical insights and strategies for adopting MWA in diverse clinical settings. Upon completing the program, both physicians were awarded Certificates of Completion, signifying their readiness to incorporate this advanced treatment modality into their practice.

"Advancing the development of MWA for thyroid nodules requires hands-on training and expert collaboration," said Haimei Wu, Chairwoman of Baird Medical. "By supporting specialized programs like this, we are empowering physicians with the practical expertise needed to refine patient care and drive broader adoption of minimally invasive thyroid treatments."

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-sponsored-microwave-ablation-training-advances-thyroid-treatment-302348718.html

SOURCE BDMD

FAQ

What was the purpose of Baird Medical's (BDMD) recent MWA training session in New Orleans?

The training session aimed to provide physicians with practical experience in Microwave Ablation technology for thyroid nodule treatment, focusing on technique refinement and clinical adoption.

How many live MWA procedures were performed during BDMD's training session?

Seven live MWA procedures were performed during the training session, allowing physicians to observe and learn the technique.

Who led Baird Medical's (BDMD) MWA training program in New Orleans?

Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, led the training program.

What are the key benefits of BDMD's Microwave Ablation technology for thyroid treatment?

The technology offers quicker recovery times, effective management of thyroid nodules, and features a streamlined workflow for enhanced patient outcomes.
Baird Medical

NASDAQ:BDMD

BDMD Rankings

BDMD Latest News

BDMD Stock Data

51.78M
31.27M
99.92%
2.11%
0.16%
Medical Devices
Healthcare
Link
China
Guangzhou